Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | CTSV | O60911 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096277 | 0.83 | LTA4H (0.47) | SRD5A2SIRT2MAPTMAPK1TDP1 | |
| SCHEMBL6094641 | 0.82 | HTR2A (0.44) | HTR2AMAPT | |
| SCHEMBL6095982 | 0.79 | HTR2A (0.45) | HTR2AMAOBSRD5A2PTGER1EDNRA | |
| SCHEMBL6093904 | 0.78 | TRPM8 (0.48) | MAOBMAPTMAOAHPGDCTSV | |
| SCHEMBL6096903 | 0.78 | GPR84 (0.42) | SIRT2 | |
| SCHEMBL6097076 | 0.76 | GPR84 (0.40) | HTR2ASIRT2 | |
| SCHEMBL6094532 | 0.76 | HTR2A (0.40) | HTR2ASIRT2 | |
| SCHEMBL6096170 | 0.76 | CYP2A6 (0.41) | — | |
| SCHEMBL9085416 | 0.75 | PRKCB (0.59) | HTR2ASIRT2 | |
| SCHEMBL6097734 | 0.72 | PRKCB (0.54) | SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057052-B2 | Heterocyclic quinones as pharmaceutical agents | DUKE UNIVERSITY (US) | 2006-06-06 | — | — | US | disclosed |
| WO-2004050014-A2 | SETEROCYCLIC QUINONES AS PHARMACEUTICAL AGENTS | DUKE UNIVERSITY (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040063774-A1 | Heterocyclic quinones as pharmaceutical agents | DUKE UNIVERSITY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063774-A1 | Heterocyclic quinones as pharmaceutical agents | NQO1, RECQL, SDHA | HTR2A 1843/4885MAOB 266/4885SRD5A2 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.